Published in Int J Endocrinol on January 31, 2015
Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging (2016) 0.85
Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res (2017) 0.81
The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. Nat Rev Urol (2016) 0.78
The best of both worlds - managing the cancer, saving the bone. Nat Rev Endocrinol (2015) 0.75
From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases. Ther Adv Med Oncol (2016) 0.75
Cancer-targeted therapies and radiopharmaceuticals. Bonekey Rep (2015) 0.75
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Bone morphogenetic proteins. Growth Factors (2004) 8.61
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Osteoporosis: now and the future. Lancet (2011) 5.81
Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol (2012) 4.87
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2013) 4.65
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol (2003) 3.73
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol (2014) 3.40
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol (2014) 3.03
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst (2007) 2.86
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst (2003) 2.68
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med (1995) 2.50
Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res (2004) 2.47
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol (2014) 2.31
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol (2009) 2.18
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol (2002) 2.03
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2013) 1.95
Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology (2005) 1.85
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. Eur Urol (2014) 1.81
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol (2014) 1.71
Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res (1999) 1.57
Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res (2005) 1.56
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res (2003) 1.55
Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer (2014) 1.53
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol (2006) 1.44
Biochemical markers and skeletal metastases. Cancer (2000) 1.40
Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol (2003) 1.37
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol (2003) 1.35
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer (2012) 1.16
Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate (2010) 1.15
Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2011) 1.14
Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol (2006) 1.13
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol (2007) 1.10
Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer (2013) 1.10
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol (2014) 1.10
Zometa European Study (ZEUS): another failed crusade for the holy grail of prostate cancer bone metastases prevention? Eur Urol (2014) 1.09
Cancer-associated bone disease. Osteoporos Int (2013) 0.94
Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Pract Res Clin Endocrinol Metab (2013) 0.93
Male osteoporosis. Endocrinol Metab Clin North Am (2012) 0.92
Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Lett (2014) 0.91
Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation. Clin Exp Metastasis (2009) 0.89
Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol (2014) 0.87
Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis. Prostate (2004) 0.87
Muscle and bone effects of androgen deprivation therapy: current and emerging therapies. Endocr Relat Cancer (2014) 0.85
Niche competition and cancer metastasis to bone. J Clin Invest (2011) 0.85
Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. Osteoporos Int (2013) 0.81
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression? World J Urol (2012) 0.80
Bone health management in prostate cancer patients receiving androgen deprivation therapy. J Oncol Pharm Pract (2011) 0.80
Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the end point's definition? Ann Oncol (2014) 0.77
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. Clin Genitourin Cancer (2013) 0.76